Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.12+0.12 (+2.00%)
At close: 04:00PM EST
6.20 +0.08 (+1.31%)
After hours: 04:56PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.00
Open5.88
Bid6.05 x 1300
Ask6.20 x 900
Day's Range5.85 - 6.20
52 Week Range5.59 - 14.40
Volume274,710
Avg. Volume288,903
Market Cap168.973M
Beta (5Y Monthly)-0.13
PE Ratio (TTM)N/A
EPS (TTM)-2.28
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.57
  • GlobeNewswire

    NextCure to Present at The JMP Securities Hematology and Oncology Summit

    BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday December 7th at 11:40 am ET. A live audio webcast will be available through the Investors section of the company’s website

  • GlobeNewswire

    NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

    BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th. An audio webcast of the pre-recorded fireside chat will be available today at 10 a.m. ET through the Investors section of th

  • GlobeNewswire

    NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

    BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC

Advertisement
Advertisement